1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Slides:

Advertisements

Similar presentations

Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.

Advertisements

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.

Anesthetic and Life Support Drugs, and Drug Safety and Risk Management Advisory Committees, November 13, 2008 Outpatient Drug Utilization Trends for Oxycodone.

Nonprescription Simvastatin in the United Kingdom Michael L. Koenig, Ph.D. Interdisciplinary Scientist Division of Over-the-Counter Drug Products Center.

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

Center for Drug Evaluation and Research Patterns of Prescription Weight-Loss Drug Use Endocrinologic and Metabolic Drugs Advisory Committee Meeting Rockville,

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

1 One Year Post-Pediatric Exclusivity Postmarketing Adverse Event Review SERTRALINE ( Zoloft) Dr. Solomon Iyasu Medical Team Leader Division of Pediatric.

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

Praluent® - alirocumab

Pediatric Advisory Committee April 11, Update to the Committee: Oxybutynin Central Anticholinergic Effects Pediatric Advisory Committee Meeting.

DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENATIONS.

Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.

Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, Overview Isotretinoin Pregnancy Exposures:

Periodontal Health and Birth Outcomes Secretary’s Advisory Committee on Infant Mortality – SACIM November 30, 2006 M. Ann Drum, DDS, MPH, Director Department.

Regulatory History of Sibutramine Eric Colman, MD Division of Metabolism and Endocrinology Products CDER - FDA.

1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 One Year Post Exclusivity Adverse Event Review: Topotecan Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 One Year Post-Exclusivity Adverse Event Review: Paricalcitol, Zolmitriptan, Dorzolamide, and Leflunomide Pediatric Advisory Committee Meeting June 29,

Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, 2004 RISK MANAGEMENT OPTIONS FOR PREGNANCY.

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.

1 One Year Post Exclusivity Adverse Event Review: Esmolol Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer Division.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Sidney M. Wolfe M.D and Sherri Shubin M.D., M.P.H. Public Citizen’s Health Research Group FDA Drug Safety and Risk Management and Dermatologic and Ophthalmic.

Mevacor 20 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees December 13, 2007 Andrea Leonard-Segal, M.D.

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 Meeting of the Advisory Committee for Reproductive Health Drugs August 29, 2006 Scott Monroe, MD Acting Director, Division of Reproductive and Urologic.

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

History of Pediatric Labeling

1 One Year Post-Exclusivity Adverse Event Review: Rosiglitazone Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 One Year Post-Exclusivity Adverse Event Review: Insulin Aspart Recombinant Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs,

Endocrinologic & Metabolic Drugs Advisory Committee Meeting

1 One Year Post Exclusivity Adverse Event Review: Sibutramine Pediatric Advisory Committee Meeting March 22, 2006 Hari Cheryl Sachs, MD, FAAP Medical Officer.

Advisory Committee Presentation on Vioxx (Rofecoxib) Discussion on the meta analyses for cardiovascular risk assessment Qian Li, Sc. D.

Food and Drug Administration Amendments Act of 2007 Reauthorization of Pediatric Initiatives Lisa L. Mathis, M.D. Pediatric and Maternal Health Staff Office.

Drugs Susan Louw Haematology Registrar. 4 Questions to ask: Can I stop? (What is the risk of thrombosis?) Should I stop? (What is the risk of bleeding?)

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Initiatives Drive Pediatric Drug Development January 30, 2002.

Modafinil for the Treatment of ADHD Paul J. Andreason, MD Acting Deputy Director Division of Psychiatry Products Center for Drug Evaluation and Research,

Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015

1 The Role of Exposure-Response Evaluation in Drug Development and Regulatory Decisions Case Study: Rosuvastatin Hae-Young Ahn, Ph.D. Office of Clinical.

Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

1 One Year Post Exclusivity Adverse Event Review: Benazepril Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.

Application of the 1998 Pediatric Rule to Oncology Steven Hirschfeld, MD PhD CDR U.S. Public Health Service Medical Officer Division of Oncology Drug Products.

Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation.

C-1 Safety Results S. aureus Bacteremia and Endocarditis Study Gloria Vigliani, M.D. Vice President, Medical Strategy Cubist Pharmaceuticals.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

1 Joint NDAC/EMDAC Meeting January 13, 2005 Mevacor TM Daily 20 mg Tablets Rx-to-OTC Switch Daiva Shetty, M.D. Division of Over-the-Counter Drug Products.

Pediatric Advisory Committee: Overview of Role and Evolution of Process Dr. Dianne Murphy Director, Office of Pediatric Therapeutics, OC, FDA November.

1 One Year Post Exclusivity Adverse Event Review: Glyburide-Metformin Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP.

Use of Acyclovir, Valacyclovir, and Famciclovir in the First Trimester of Pregnancy and the Risk of Birth Defects Björn Pasternak; Anders Hviid R3 Jungwook.

Intensive Statin Recommendations

Drug induced myopathy Edition

17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study David B. Nelson, MD; Donald D. McIntire,

Clinicians' Corner in Dyslipidemia

Train-the-Trainer Cases

Pandemic Lipid Edition

Train-the-Trainer Cases

Train-the-Trainer Cases

Presentation transcript:

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting Medical Team Leader Pediatric and Maternal Health Staff Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration

2 Background Drug Information Drug: Zocor ® (simvastatin) Therapeutic Category: lipid-lowering agent Sponsor: Merck & Co., Inc. Original Market Approval: December 23, 1991 Pediatric Exclusivity Granted: February 22, 2002 Mechanism of action: inhibitor of HMG-CoA reductase

3 Background Drug Information Pediatric Indication: adjunct to diet to reduce total-C, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present –LDL-C remains >190 mg/dl or –LDL-C remains >160 mg/dl and there is a positive family history of premature CVD or >2 CVD risk factors are present Pediatric Dosage: –initial dose 10 mg daily with maximum 40 mg daily

4 Background Drug Information Pediatric Indication: to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable. Dosage: mg daily

5 Simvastatin: Pediatric Drug Use Trends 1 Pediatric use is small (< 0.1% of total number of prescriptions dispensed in retail pharmacies) # of pediatric prescriptions dispensed by year: –in 2002: 13,498 prescriptions –in 2003: 12,397 –in 2004: 11,427 –in 2005: 10,466 1 Verispan, Vector One ® : National (VONA), data extracted Sep 2006

6 Simvastatin: Pediatric Adverse Events 4 reports during the one year post exclusivity (2/22/02-3/22/03) –All serious, including one death –2 post-natal (↑LDH: also on ibuprofen; ↑CPK and neuroleptic malignant syndrome: also on zuclopenthixol) –2 in utero exposures (fetal distress but healthy newborn; pre-term birth (32 weeks), severe hypotrophy, IUGR, post-natal death (day 3 of “prematurity”), multiple maternal concomitant medications) –Conclusion: reports confounded by concomitant medications and/or underlying illness

7 Simvastatin: Pediatric Adverse Events 6 (0.13% of total reports for all ages) during the subsequent three year period (3/22/03-8/22/06) –All serious, including one death –3 post-natal reports in children 6-14 years –3 (?4) in utero exposures (included 1 spontaneous miscarriage); pregnancy category X

8 Simvastatin: Pediatric Post-Natal Adverse Events (3/22/03-8/22/06) 3 reports in patients aged 6-14 years –2 reports: ↑CPK; one also with muscle stiffness and chest pain ; both with concomitant medications (one with cyclosporine) (labeled) –1 Thrombotic thrombocytopenic purpura (TTP) (unlabeled): confounded by underlying disease (systemic lupus erythematosis and Sjogren’s syndrome) and concomitant medications

9 Simvastatin: In Utero Exposures (n=3, ?4) (3/22/03-8/22/06) –Spontaneous miscarriage; simvastatin during first 2 weeks of pregnancy –Skin outgrowth fifth finger of left hand with anlage of a fingernail; simvastatin weeks 2-4 and salbutamol month 7 of pregnancy –Lower limb deformity; 1 st trimester exposure; multiple concomitant medications (aspirin, acteaminophen, codeine and propoxyphene) –VACTERL association; first trimester exposure; concomitant medication (promegestone) a a= Edison RJ and Muenke M. New England Journal of Medicine 2004;350(15):

10 Summary: Simvastatin One pediatric unlabeled post-natal adverse event, TTP, confounded by underlying illness and concomitant medications In utero exposures: Pregnancy category X The FDA recommends routine monitoring of simvastatin for AEs in all populations Does the Advisory Committee concur?

11 Acknowledgements OSE Jennie Chang Laura Governale David Moeny Jo Wyeth Rosemary Johann-Liang PMHS Lisa Mathis Kristin Phucas DMEP Eric Colman Eileen Craig